Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model

Detalhes bibliográficos
Autor(a) principal: Fraga, Michelle
Data de Publicação: 2017
Outros Autores: Carvalho, Talita Giacomet de, Bidone, Juliana, Schuh, Roselena Silvestri, Matte, Ursula da Silveira, Teixeira, Helder Ferreira
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/172598
Resumo: Mucopolysaccharidosis type I (MPS I) is an autosomal disease caused by alpha-l-iduronidase (IDUA) deficiency. This study used IDUA knockout mice as a model to evaluate whether parameters such as dose of plasmid and time of treatment could influence the transfection efficiency of complexes formed with PEGylated cationic nanoemulsions and plasmid (pIDUA), which contains the gene that encodes for IDUA. Formulations were composed of medium chain triglycerides, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(amino[polyethylene glycol]-2000), 1,2-dioleoyl-sn-glycero-3-trimethylammonium propane (DOTAP), glycerol, and water and were prepared by the adsorption or encapsulation of preformed pIDUA–DOTAP complexes by high-pressure homogenization. A progressive increase in IDUA expression was observed with an increase in the dose and time of transfection for mice treated with both complexes (adsorbed and encapsulated), especially in the liver. Regardless of the complex administered, a significant increase in IDUA activity was detected in lungs and liver compared with nontreated MPS I when a dose of 60 μg was administered and IDUA activity was measured 7 days postadministration. Tissue sections of major organs showed no presence of cell necrosis, inflammatory infiltrate, or an increase in apoptosis. Furthermore, immunohistochemistry for CD68 showed no difference in the number of macrophage cells in treated and nontreated animals, indicating the absence of inflammatory reaction caused by the treatment. The data set obtained in this study allowed establishing that factors such as dose and time can influence transfection efficiency in different degrees and that these complexes did not lead to any lethal effect in the MPS I murine model used.
id UFRGS-2_dc7bb2ac5b5617081a1206a92f87ec4e
oai_identifier_str oai:www.lume.ufrgs.br:10183/172598
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Fraga, MichelleCarvalho, Talita Giacomet deBidone, JulianaSchuh, Roselena SilvestriMatte, Ursula da SilveiraTeixeira, Helder Ferreira2018-02-16T02:29:58Z20171178-2013http://hdl.handle.net/10183/172598001019632Mucopolysaccharidosis type I (MPS I) is an autosomal disease caused by alpha-l-iduronidase (IDUA) deficiency. This study used IDUA knockout mice as a model to evaluate whether parameters such as dose of plasmid and time of treatment could influence the transfection efficiency of complexes formed with PEGylated cationic nanoemulsions and plasmid (pIDUA), which contains the gene that encodes for IDUA. Formulations were composed of medium chain triglycerides, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(amino[polyethylene glycol]-2000), 1,2-dioleoyl-sn-glycero-3-trimethylammonium propane (DOTAP), glycerol, and water and were prepared by the adsorption or encapsulation of preformed pIDUA–DOTAP complexes by high-pressure homogenization. A progressive increase in IDUA expression was observed with an increase in the dose and time of transfection for mice treated with both complexes (adsorbed and encapsulated), especially in the liver. Regardless of the complex administered, a significant increase in IDUA activity was detected in lungs and liver compared with nontreated MPS I when a dose of 60 μg was administered and IDUA activity was measured 7 days postadministration. Tissue sections of major organs showed no presence of cell necrosis, inflammatory infiltrate, or an increase in apoptosis. Furthermore, immunohistochemistry for CD68 showed no difference in the number of macrophage cells in treated and nontreated animals, indicating the absence of inflammatory reaction caused by the treatment. The data set obtained in this study allowed establishing that factors such as dose and time can influence transfection efficiency in different degrees and that these complexes did not lead to any lethal effect in the MPS I murine model used.application/pdfengInternational Journal of Nanomedicine. Manchester. Vol. 12 (Mar. 2017), p. 2061-2067NanotecnologiaNanoemulsõesCationic nanoemulsionsDSPE-PEGMPS IPlasmidpIDUAFactors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine modelEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL001019632.pdf001019632.pdfTexto completo (inglês)application/pdf3124441http://www.lume.ufrgs.br/bitstream/10183/172598/1/001019632.pdfe929902d29cd9e748dd744c2aa0455dcMD51TEXT001019632.pdf.txt001019632.pdf.txtExtracted Texttext/plain28236http://www.lume.ufrgs.br/bitstream/10183/172598/2/001019632.pdf.txta8110c4a2356916086bf33083affdc06MD52THUMBNAIL001019632.pdf.jpg001019632.pdf.jpgGenerated Thumbnailimage/jpeg1972http://www.lume.ufrgs.br/bitstream/10183/172598/3/001019632.pdf.jpgedf0943f060034ef75eaf1ef73a6b97bMD5310183/1725982018-10-26 10:23:15.632oai:www.lume.ufrgs.br:10183/172598Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2018-10-26T13:23:15Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model
title Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model
spellingShingle Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model
Fraga, Michelle
Nanotecnologia
Nanoemulsões
Cationic nanoemulsions
DSPE-PEG
MPS I
Plasmid
pIDUA
title_short Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model
title_full Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model
title_fullStr Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model
title_full_unstemmed Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model
title_sort Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model
author Fraga, Michelle
author_facet Fraga, Michelle
Carvalho, Talita Giacomet de
Bidone, Juliana
Schuh, Roselena Silvestri
Matte, Ursula da Silveira
Teixeira, Helder Ferreira
author_role author
author2 Carvalho, Talita Giacomet de
Bidone, Juliana
Schuh, Roselena Silvestri
Matte, Ursula da Silveira
Teixeira, Helder Ferreira
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Fraga, Michelle
Carvalho, Talita Giacomet de
Bidone, Juliana
Schuh, Roselena Silvestri
Matte, Ursula da Silveira
Teixeira, Helder Ferreira
dc.subject.por.fl_str_mv Nanotecnologia
Nanoemulsões
topic Nanotecnologia
Nanoemulsões
Cationic nanoemulsions
DSPE-PEG
MPS I
Plasmid
pIDUA
dc.subject.eng.fl_str_mv Cationic nanoemulsions
DSPE-PEG
MPS I
Plasmid
pIDUA
description Mucopolysaccharidosis type I (MPS I) is an autosomal disease caused by alpha-l-iduronidase (IDUA) deficiency. This study used IDUA knockout mice as a model to evaluate whether parameters such as dose of plasmid and time of treatment could influence the transfection efficiency of complexes formed with PEGylated cationic nanoemulsions and plasmid (pIDUA), which contains the gene that encodes for IDUA. Formulations were composed of medium chain triglycerides, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(amino[polyethylene glycol]-2000), 1,2-dioleoyl-sn-glycero-3-trimethylammonium propane (DOTAP), glycerol, and water and were prepared by the adsorption or encapsulation of preformed pIDUA–DOTAP complexes by high-pressure homogenization. A progressive increase in IDUA expression was observed with an increase in the dose and time of transfection for mice treated with both complexes (adsorbed and encapsulated), especially in the liver. Regardless of the complex administered, a significant increase in IDUA activity was detected in lungs and liver compared with nontreated MPS I when a dose of 60 μg was administered and IDUA activity was measured 7 days postadministration. Tissue sections of major organs showed no presence of cell necrosis, inflammatory infiltrate, or an increase in apoptosis. Furthermore, immunohistochemistry for CD68 showed no difference in the number of macrophage cells in treated and nontreated animals, indicating the absence of inflammatory reaction caused by the treatment. The data set obtained in this study allowed establishing that factors such as dose and time can influence transfection efficiency in different degrees and that these complexes did not lead to any lethal effect in the MPS I murine model used.
publishDate 2017
dc.date.issued.fl_str_mv 2017
dc.date.accessioned.fl_str_mv 2018-02-16T02:29:58Z
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/172598
dc.identifier.issn.pt_BR.fl_str_mv 1178-2013
dc.identifier.nrb.pt_BR.fl_str_mv 001019632
identifier_str_mv 1178-2013
001019632
url http://hdl.handle.net/10183/172598
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv International Journal of Nanomedicine. Manchester. Vol. 12 (Mar. 2017), p. 2061-2067
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/172598/1/001019632.pdf
http://www.lume.ufrgs.br/bitstream/10183/172598/2/001019632.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/172598/3/001019632.pdf.jpg
bitstream.checksum.fl_str_mv e929902d29cd9e748dd744c2aa0455dc
a8110c4a2356916086bf33083affdc06
edf0943f060034ef75eaf1ef73a6b97b
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1801224936671412224